AU2021390130A1 - Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19 - Google Patents

Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19 Download PDF

Info

Publication number
AU2021390130A1
AU2021390130A1 AU2021390130A AU2021390130A AU2021390130A1 AU 2021390130 A1 AU2021390130 A1 AU 2021390130A1 AU 2021390130 A AU2021390130 A AU 2021390130A AU 2021390130 A AU2021390130 A AU 2021390130A AU 2021390130 A1 AU2021390130 A1 AU 2021390130A1
Authority
AU
Australia
Prior art keywords
seq
sars
cov
sirna
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021390130A
Other languages
English (en)
Other versions
AU2021390130A9 (en
Inventor
Yi-Chung Chang
Yi-Fen Chen
Yuan-Lin CHOU
Chi-Fan Yang
Chia-Chun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbio Shanghai Co Ltd
Oneness Biotech Co Ltd
Original Assignee
Microbio Shanghai Co Ltd
Oneness Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbio Shanghai Co Ltd, Oneness Biotech Co Ltd filed Critical Microbio Shanghai Co Ltd
Publication of AU2021390130A1 publication Critical patent/AU2021390130A1/en
Publication of AU2021390130A9 publication Critical patent/AU2021390130A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021390130A 2020-12-03 2021-12-03 Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19 Pending AU2021390130A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/133565 2020-12-03
CN2020133565 2020-12-03
CNPCT/CN2021/121762 2021-09-29
CN2021121762 2021-09-29
PCT/CN2021/135476 WO2022117085A1 (en) 2020-12-03 2021-12-03 Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19

Publications (2)

Publication Number Publication Date
AU2021390130A1 true AU2021390130A1 (en) 2023-06-29
AU2021390130A9 AU2021390130A9 (en) 2025-04-03

Family

ID=81853844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021390130A Pending AU2021390130A1 (en) 2020-12-03 2021-12-03 Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19

Country Status (8)

Country Link
US (1) US20240026362A1 (https=)
EP (1) EP4256055A4 (https=)
JP (1) JP2023553610A (https=)
KR (1) KR20230142701A (https=)
CN (1) CN116964202A (https=)
AU (1) AU2021390130A1 (https=)
IL (1) IL303367A (https=)
WO (1) WO2022117085A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919267B (zh) * 2024-01-24 2024-12-03 石河子大学 miR2911在制备抗猪繁殖与呼吸障碍综合症病毒的药物中的应用
CN118001297B (zh) * 2024-02-01 2025-01-28 中国人民解放军军事科学院军事医学研究院 一种治疗SARS-CoV-2及其变体感染的多功能组合物及其制备方法
CN118853668A (zh) * 2024-06-24 2024-10-29 中山大学 一种靶向SARS-CoV-2的siRNA自组装纳米颗粒及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443765T1 (de) * 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子（SiRNA）及应用
CN101113158A (zh) * 2006-12-18 2008-01-30 四川大学 干扰SARS病毒RdRp基因功能的siRNA
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2021183887A1 (en) * 2020-03-13 2021-09-16 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for viral genome targeting
TW202204615A (zh) * 2020-03-26 2022-02-01 美商阿尼拉製藥公司 冠狀病毒ｉＲＮＡ組成物及其使用方法
CN111778253B (zh) * 2020-04-03 2022-02-18 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111748557B (zh) * 2020-04-03 2022-03-11 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
AU2021251249A1 (en) * 2020-04-10 2022-11-10 Aligos Therapeutics, Inc. Short interfering nucleic acid (siNA) molecules and uses thereof for coronavirus diseases
CN111518809A (zh) * 2020-05-12 2020-08-11 杭州勇诚睿生物科技有限公司 干扰新冠病毒COVID-19基因表达的siRNA及其应用
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией
EP4359528A1 (en) * 2021-06-25 2024-05-01 Alpine Antiviral GmbH Sirna combinations targeting sars-cov-2 and/or host factor transcripts

Also Published As

Publication number Publication date
IL303367A (en) 2023-08-01
CN116964202A (zh) 2023-10-27
EP4256055A4 (en) 2025-07-02
KR20230142701A (ko) 2023-10-11
WO2022117085A1 (en) 2022-06-09
AU2021390130A9 (en) 2025-04-03
JP2023553610A (ja) 2023-12-25
US20240026362A1 (en) 2024-01-25
EP4256055A1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
Chang et al. A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
WO2022117085A1 (en) Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19
EP3344772B1 (en) Antagonistic pdl1 aptamers and their applications in cancer therapy
JP2014177496A (ja) Ｒｓｖ感染の予防または治療のための方法および組成物
US20140287023A1 (en) 5'-triphosphate oligoribonucleotides
US20250101428A1 (en) Modification patterns for small interfering rna molecules with high stability and gene silencing activities
US20140323541A1 (en) Methods And Compositions For Prevention Or Treatment Of RSV Infection Using Modified Duplex RNA Molecules
CN114729360A (zh) 降低病毒分子水平的方法
WO2021237297A1 (en) Anti-viral extracellular vesicles, their methods of preparation and uses
CN105555279B (zh) 用于治疗脓毒症的MicroRNA抑制
US20240425853A1 (en) Modified small interfering rna molecules with reduced off-target effects
US20230226095A1 (en) Methods and compositions for treating coronavirus infectious disease
WO2026067447A1 (en) Small Interfering RNAs Targeting ANT2 and Uses Thereof for Disease Treatment
US20250367185A1 (en) Translesion synthesis polymerase inhibitors and uses thereof
US11883395B2 (en) Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
Gharib Mombeni et al. Recent drugs and vaccines candidates to tackle COVID-19
CN118320091A (zh) 胱天蛋白酶抑制剂的组合物及其使用方法
Kim et al. Duox2-derived reactive oxygen species induce pattern recognition receptors’ expression against influenza A virus in nasal mucosa
EP4208550A1 (en) Antiviral silencing rna molecules, chemically modified antiviral silencing rna molecules with enhanced cell penetrating abilities, pharmaceutical compositions comprising same and uses thereof for treatment of viral infections

Legal Events

Date Code Title Description
SREP Specification republished